Alpha 2.0
Login Register
» Authors » Bernard D Gary

Bernard D Gary

Explore the profile of Bernard D Gary including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 542
Followers 0
Related Specialties
Chemistry
Oncology
Pharmacy
Top 10 Co-Authors
Gary A Piazza
Heather N Tinsley
Ashraf H Abadi
Adam B Keeton
Nan Li
Jason D Whitt
Robert C Reynolds
Nermin S Ahmed
Yonghe Li
Joshua C Canzoneri
Published In
Cancer Prev Res (Phila)
Eur J Med Chem
Arch Pharm (Weinheim)
Med Chem
Bioorg Med Chem
Affiliations
Soon will be listed here.
Recent Articles
1.
Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats
Tinsley H, Mathew B, Chen X, Maxuitenko Y, Li N, Lowe W, et al.
Cancers (Basel) . 2023 Feb; 15(3). PMID: 36765604
The nonsteroidal anti-inflammatory drug (NSAID) sulindac demonstrates attractive anticancer activity, but the toxicity resulting from cyclooxygenase (COX) inhibition and the suppression of physiologically important prostaglandins precludes its long-term, high dose...
2.
Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion
Whitt J, Keeton A, Gary B, Sklar L, Sodani K, Chen Z, et al.
J Biomed Res . 2017 Mar; 30(2):120-133. PMID: 28276667
ATP-binding cassette (ABC) transporters ABCC1 (MRP1), ABCB1 (P-gp), and ABCG2 (BCRP) contribute to chemotherapy failure. The primary goals of this study were to characterize the efficacy and mechanism of the...
3.
NSAIDs: Old Drugs Reveal New Anticancer Targets
Piazza G, Keeton A, Tinsley H, Whitt J, Gary B, Mathew B, et al.
Pharmaceuticals (Basel) . 2016 Oct; 3(5):1652-1667. PMID: 27713322
There is compelling evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 selective inhibitors have antineoplastic activity, but toxicity from cyclooxygenase (COX) inhibition and the suppression of physiologically important prostaglandins limits...
4.
Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention
Aboul-Fadl T, Al-Hamad S, Lee K, Li N, Gary B, Keeton A, et al.
Med Chem Res . 2016 Aug; 23(9):4177-4188. PMID: 27559271
A structure-based medicinal chemistry strategy was applied to design new naproxen derivatives that show growth inhibitory activity against human colon tumor cells through a cyclooxygenase (COX)-independent mechanism. In vitro testing...
5.
Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors
Abdel-Rahman H, Abdel-Aziz M, Tinsley H, Gary B, Canzoneri J, Piazza G
Arch Pharm (Weinheim) . 2015 Dec; 349(2):104-11. PMID: 26686665
A series of novel pyridazin-6-one-1-acetylhydrazone hybrids were rationally designed to inhibit phosphodiesterase 4 (PDE4B). The prepared compounds were evaluated for their in vitro ability to inhibit the PDE4B enzyme; several...
6.
Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach
Hassaan E, Sigler S, Ibrahim T, Lee K, Cichon L, Gary B, et al.
Med Chem . 2015 Dec; 12(5):472-7. PMID: 26648332
In view of the emerging clinical indications for Phosphodiesterase 9 inhibitors e.g. treatment of Alzheimer, diabetes, cancer, and the limited number of its selective inhibitors which possess a single chemical...
7.
Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies
Abdel-Rahman H, Abdel-Aziz M, Canzoneri J, Gary B, Piazza G
Arch Pharm (Weinheim) . 2014 Jul; 347(9):650-7. PMID: 24985336
A novel series of quinazolin-4(3H)-one/Schiff base hybrids was rationally designed and synthesized. The prepared compounds were evaluated for in vitro activity to inhibit phosphodiesterase 4 (PDE4), where several of them...
8.
Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer
Arora R, Yates C, Gary B, McClellan S, Tan M, Xi Y, et al.
PLoS One . 2014 Jun; 9(6):e98370. PMID: 24896091
Background: Triple-negative breast cancer (TNBC) is a highly diverse group that is associated with an aggressive phenotype. Its treatment has been challenging due to its heterogeneity and absence of well-defined...
9.
Synthesis of some dihydropyrimidine-based compounds bearing pyrazoline moiety and evaluation of their antiproliferative activity
Awadallah F, Piazza G, Gary B, Keeton A, Canzoneri J
Eur J Med Chem . 2013 Oct; 70:273-9. PMID: 24161704
Two series of 2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-1-methyl-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitriles 5a-h and 4-(4-chlorophenyl)-2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitriles 6a-h were synthesized via a cyclocondensation reaction of the corresponding 2-hydrazinopyrimidines 3a,b with the appropriate 2-propen-1-ones 4a-h. The target compounds were screened for...
10.
Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53
Abdel-Halim M, Keeton A, Gurpinar E, Gary B, Vogel S, Engel M, et al.
Bioorg Med Chem . 2013 Oct; 21(23):7343-56. PMID: 24139845
Derivatives with scaffolds of 1,3,5-tri-substituted pyrazoline and 1,3,4,5-tetra-substituted pyrazoline were synthesized and tested for their inhibitory effects versus the p53(+/+) HCT116 and p53(-/-) H1299 human tumor cell lines. Several compounds...